A U.S.-headquartered multinational life sciences corporation develops, manufactures, and sells reagents, instruments, and provides services for the research, diagnostic, and bioprocessing markets. The firm is actively seeking opportunities aligned with its current pipeline and business, such as life science tools and services, diagnostics, spatial biology, and tech-bio. The firm primarily focuses on mergers and acquisitions, but equity investments are also possible. For equity investments, the sweet spot is around Series A and the firm prefers co-investment opportunities and may seek board or observer seats on a case-by-case basis. The firm is primarily interested in opportunities based in the U.S. and Europe.
The firm is focused on tools and services, diagnostics, spatial biology, and tech-bio, such as platforms that enhance biopharma R&D and academic research. Technologies or products with strong strategic alignment to the corporation are preferred. The firm prioritizes companies that have a working prototype and ideally are already on the market, generating revenue. However, for equity investments, earlier-stage disruptive technologies may also be considered.
The firm does not have specific requirements regarding a company’s founding team.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment